← All trials
NCT06047977
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2024
- Primary completion
- Dec 1, 2026
- Completion date
- Dec 1, 2027
- First posted
- Sep 21, 2023
- Last posted
- Dec 15, 2023
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of South FloridaLead sponsor
- Johns Hopkins UniversityLead sponsor
- Cannonball Kids' Cancer FoundationCollaborator
- Johns Hopkins UniversityOverall official - principal investigator
- Swim Across AmericaCollaborator
- Johns Hopkins UniversityOfficial
- University of South FloridaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.